{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03047772",
      "OrgStudyIdInfo": {
        "OrgStudyId": "2016-807-10.1"
      },
      "Organization": {
        "OrgFullName": "Chinese Academy of Medical Sciences, Fuwai Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients",
      "OfficialTitle": "The Randomized Double-blind Placebo-Controlled Multi-center Clinical Trial of Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in Acute Myocardial Infarction Patients",
      "Acronym": "TEAM-AMI"
    },
    "StatusModule": {
      "StatusVerifiedDate": "January 2018",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 6, 2018",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 31, 2018",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 31, 2018",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "February 7, 2017",
      "StudyFirstSubmitQCDate": "February 7, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "February 9, 2017",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "January 23, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 25, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor-Investigator",
        "ResponsiblePartyInvestigatorFullName": "Yuejin Yang",
        "ResponsiblePartyInvestigatorTitle": "Vice Dean of Fuwai hospital",
        "ResponsiblePartyInvestigatorAffiliation": "Chinese Academy of Medical Sciences, Fuwai Hospital"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Yuejin Yang",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Peking Union Medical College Hospital",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "The First Hospital of Hebei Medical University",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Zunyi Medical College",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No",
      "IsUSExport": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The benefit of current stem cell transplantation therapy for myocardial infarction is limited by low survival rate for stem cell. The purpose of this study is to test whether intensive Atorvastatin therapy can improve the outcome of patients with impaired left ventricle function after acute myocardial infarction who underwent intracoronary transfer of autologous bone marrow mesenchymal stem cells.",
      "DetailedDescription": "The major challenge to a successful stem cell therapy for myocardial infarction is the low survival rate of implanted cells in the damaged tissue. Atorvastatin, an HMG-CoA reductase inhibitor, has multiple biological activities independent of cholesterol-lowering action.This study is performed to find out more information about the strategy with Atorvastatin therapy to improve the survival of implanted cells, autologous bone marrow mesenchymal stem cells transplantation. Patients between 30 and 75 years of age who receive autologous bone marrow mesenchymal stem cells transplant may be eligible for this study. These patients receive autologous bone marrow mesenchymal stem cells transplantation intracoronary undergoing Percutaneous Coronary Intervention with regular or high dose of Atorvastatin treatment. The objective evaluations will be performed at baseline and during 12 months follow-up.\n\nHeart function tests may include the following:\n\nElectrocardiogram (EKG) evaluates the electrical activity of the heart. Electrodes placed on the chest transmit information from the heart to a machine.\n\nEchocardiogram (Echo) is an ultrasound test that uses sound waves to create an image of the heart and examine the function of the heart chambers and valves.\n\nGated acquisition scan is a nuclear medicine test that uses a small amount of radioactive chemical injected into a vein. A special scanner creates an image of the heart for examining the beating motion of the muscle.\n\nMRI evaluates function of the heart chambers the beating motion of the muscle."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Myocardial Infarction",
          "Stem Cell Transplantation",
          "Angioplasty, Transluminal, Percutaneous Coronary"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Factorial Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "124",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Phase A: Atorvastatin",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Atorvastatin routine dose + placebo transplantation",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Atorvastatin"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase A: Low dose BMMSC",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Atorvastatin routine dose + low dose BMMSC Transplantation",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Atorvastatin",
                "Drug: Low dose BMMSC"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase A: Middle dose BMMSC",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Atorvastatin routine dose + middle dose BMMSC Transplantation",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Atorvastatin",
                "Drug: Middle dose BMMSC"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase A: High dose BMMSC",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Atorvastatin routine dose + high dose BMMSC Transplantation",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Atorvastatin",
                "Drug: High dose BMMSC"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase B: Atorvastatin",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Atorvastatin routine dose + placebo transplantation",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Atorvastatin"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase B: Atorvastatin+Transplantation",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Atorvastatin routine dose+ Optimal dose BMMSC Transplantation",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Atorvastatin",
                "Drug: Transplantation"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase B: Intensive Atorvastatin",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Atorvastatin Intensive dose + placebo transplantation",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Intensive Atorvastatin"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase B: Intensive Atorvastatin+Transplantation",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Intensive Atorvastatin",
                "Drug: Transplantation"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Atorvastatin",
            "InterventionDescription": "Routine dose of Atorvastatin therapy",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase A: Atorvastatin",
                "Phase A: High dose BMMSC",
                "Phase A: Low dose BMMSC",
                "Phase A: Middle dose BMMSC",
                "Phase B: Atorvastatin",
                "Phase B: Atorvastatin+Transplantation"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Statin"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Intensive Atorvastatin",
            "InterventionDescription": "Intensive dose of Atorvastatin therapy",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase B: Intensive Atorvastatin",
                "Phase B: Intensive Atorvastatin+Transplantation"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Low dose BMMSC",
            "InterventionDescription": "Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase A: Low dose BMMSC"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Middle dose BMMSC",
            "InterventionDescription": "Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase A: Middle dose BMMSC"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "High dose BMMSC",
            "InterventionDescription": "High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase A: High dose BMMSC"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Transplantation",
            "InterventionDescription": "Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase B: Atorvastatin+Transplantation",
                "Phase B: Intensive Atorvastatin+Transplantation"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Changes in left ventricular ejection fraction from baseline to 12 months'",
            "PrimaryOutcomeDescription": "Changes in left ventricular ejection fraction from baseline to 12 months' by MRI",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients with the first time ST-elevation myocardial infarction (STEMI).\nPatients after undergoing PCI 2 to 5 days.\nPatients without PCI but emergency coronary angiography shows the criminal coronary artery recanalized.\nLeft ventricular infarction area seriously hypokinesis or no movement\nLeft ventricular ejection fraction <=45% based on coronary angiography or echocardiography.\n\nExclusion Criteria:\n\nAny one of the following exclusion criteria is sufficient to disqualify a patient from the study.\n\nPatients without emergency PCI and the criminal coronary artery fail to be recanalized.\nPatients with non-ST-elevation myocardial infarction.\nPatients with normal left ventricular function.\nPatients with mechanical complications of myocardial infarction.\nPatients with a malignant tumor.\nPatients with infection disease.\nLess than 6 months since last episode of stroke.\nPatients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).\nALT (GPT) exceeding 100 IU/L.\nLeukocytes less than 4,000/µL or exceeding 10,000/µL.\nPlatelets less than 100,000/µL.\nHemoglobin less than 10 g/dL.\nPregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period.\nAny other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "30 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Haiyan Qian, Doctor",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "861068314466",
            "CentralContactEMail": "ahqhy712@163.com"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "31829095",
            "ReferenceType": "derived",
            "ReferenceCitation": "Xu JY, Qian HY, Huang PS, Xu J, Xiong YY, Jiang WY, Xu Y, Leng WX, Li XD, Chen GH, Tang RJ, Huang CR, Hu MJ, Jin C, Wu Y, Zhang J, Qian J, Xu B, Zhao SH, Lu MJ, Shen R, Fang W, Wu WC, Chen X, Wang Y, Li W, Lu XF, Jiang XF, Ma CC, Li JW, Geng YJ, Qiao SB, Gao RL, Yang YJ. Transplantation efficacy of autologous bone marrow mesenchymal stem cells combined with atorvastatin for acute myocardial infarction (TEAM-AMI): rationale and design of a randomized, double-blind, placebo-controlled, multi-center, Phase II TEAM-AMI trial. Regen Med. 2019 Dec;14(12):1077-1087. doi: 10.2217/rme-2019-0024. Epub 2019 Dec 12."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009203",
            "ConditionMeshTerm": "Myocardial Infarction"
          },
          {
            "ConditionMeshId": "D000007238",
            "ConditionMeshTerm": "Infarction"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007511",
            "ConditionAncestorTerm": "Ischemia"
          },
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000009336",
            "ConditionAncestorTerm": "Necrosis"
          },
          {
            "ConditionAncestorId": "D000017202",
            "ConditionAncestorTerm": "Myocardial Ischemia"
          },
          {
            "ConditionAncestorId": "D000006331",
            "ConditionAncestorTerm": "Heart Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M11307",
            "ConditionBrowseLeafName": "Myocardial Infarction",
            "ConditionBrowseLeafAsFound": "Myocardial Infarction",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9434",
            "ConditionBrowseLeafName": "Infarction",
            "ConditionBrowseLeafAsFound": "Infarction",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11436",
            "ConditionBrowseLeafName": "Necrosis",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5698",
            "ConditionBrowseLeafName": "Coronary Artery Disease",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18658",
            "ConditionBrowseLeafName": "Myocardial Ischemia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8571",
            "ConditionBrowseLeafName": "Heart Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000069059",
            "InterventionMeshTerm": "Atorvastatin"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000924",
            "InterventionAncestorTerm": "Anticholesteremic Agents"
          },
          {
            "InterventionAncestorId": "D000000960",
            "InterventionAncestorTerm": "Hypolipidemic Agents"
          },
          {
            "InterventionAncestorId": "D000000963",
            "InterventionAncestorTerm": "Antimetabolites"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          },
          {
            "InterventionAncestorId": "D000057847",
            "InterventionAncestorTerm": "Lipid Regulating Agents"
          },
          {
            "InterventionAncestorId": "D000019161",
            "InterventionAncestorTerm": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
          },
          {
            "InterventionAncestorId": "D000004791",
            "InterventionAncestorTerm": "Enzyme Inhibitors"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M351",
            "InterventionBrowseLeafName": "Atorvastatin",
            "InterventionBrowseLeafAsFound": "Duration",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M20308",
            "InterventionBrowseLeafName": "Hydroxymethylglutaryl-CoA Reductase Inhibitors",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3395",
            "InterventionBrowseLeafName": "Anticholesteremic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3430",
            "InterventionBrowseLeafName": "Hypolipidemic Agents",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3433",
            "InterventionBrowseLeafName": "Antimetabolites",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M28036",
            "InterventionBrowseLeafName": "Lipid Regulating Agents",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Lipd",
            "InterventionBrowseBranchName": "Lipid Regulating Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}